Breaking News

Tweet TWEET

Targeted Breast Radiation Linked to Higher Mastectomy Rates in Future

Breast cancer patients who undergo targeted radiation that takes less time after a tumor is removed are almost twice as likely to need a mastectomy later as women who get a full course of the treatment, a study found.

Partial radiation, known as brachytherapy, allows women to complete the twice-daily treatment in a week, compared with more than five weeks of traditional radiation. The study, reported yesterday at the San Antonio Breast Cancer Symposium, found 4 percent of those getting partial breast irradiation subsequently had a mastectomy, compared with 2.2 percent of those on standard treatment.

Researchers reviewed Medicare claims for 130,535 women diagnosed with early-stage breast cancer after menopause. They found the “strongest predictor” of whether a woman received a mastectomy was the type of radiation received, out weighing known risks such as chemotherapy, age and the amount of cancer spread, according to the study.

“Since the goal of all this therapy is to avoid cancer recurrence and preserve the breast, the fact that women treated with brachytherapy were more likely to lose their breast than women treated with whole breast radiation is concerning,” said Benjamin Smith, a study author and senior researcher at the University of Texas MD Anderson Cancer Center in Houston.

The number of women opting for the targeted therapy increased to 13 percent by 2007 from less than 1 percent in 2000, the researchers said.

Unexpected Results

The results were unexpected, said Smith. The faster intense treatment with brachytherapy, which involves inserting a catheter containing a radioactive source directly into the breast where the tumor was removed, seemed logical, he said.

The machines that deliver high-dose brachytherapy are made by companies including Varian Medical Systems Inc. (VAR), based in Palo Alto, California, and Stockholm’s Elekta AB. (EKTAB) Catheters that are inserted into the breast include Bedford, Massachusetts- based Hologic Inc. (HOLX)’s Mammosite, C.R. Bard Inc. (BCR)’s Contura and Savi from closely held Aliso Viejo, California-based Cianna Medical Inc. Only Mammosite catheters were available when the study was conducted, though newer versions have since been introduced, Smith said.

It’s unclear whether the results will apply to the newer catheters, he said.

A definitive trial comparing a variety of partial breast radiation methods to whole breast radiation is under way in more than 4,000 women, Smith said. Those results won’t be available for several years, he said.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.